Leukase N

Framycetin Sulfate, the active ingredient in Leukase N, is an aminoglycoside antibiotic presented as a topical formulation for skin application. It is used to treat superficial bacterial skin infections such as impetigo and bacterial dermatitis in patients requiring topical antibacterial therapy.

GNH USA supplies Leukase N as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to EU quality standards and provides regulatory documentation for global distribution. Customers benefit from reliable supply chains and professional technical support.

Leukase N, a topical aminoglycoside antibiotic, is indicated for bacterial skin conditions where topical therapy is appropriate.

- Superficial bacterial skin infections: reduces bacterial load and promotes healing of infected skin areas. - Impetigo: eradicates the causative Staphylococcus or Streptococcus species, limiting spread and lesion formation. - Bacterial dermatitis: controls bacterial colonisation on inflamed skin, alleviating symptoms and preventing secondary infection.

Topical application of Framycetin Sulfate may be associated with local and, rarely, systemic adverse reactions.

Common Side Effects: - Skin irritation: mild redness or discomfort at the application site. - Itching: transient pruritus localized to treated area. - Burning sensation: brief stinging feeling upon application. - Dryness: temporary loss of moisture on the skin. - Contact dermatitis: mild allergic skin reaction.

Serious or Rare Side Effects: - Allergic reaction: swelling, hives, or difficulty breathing requiring immediate medical attention. - Severe contact dermatitis: extensive rash or blistering. - Systemic toxicity: rare systemic ototoxicity or nephrotoxicity if large areas are applied. - Anaphylaxis: life‑threatening hypersensitivity reaction. - Delayed wound healing: significant inhibition of normal skin repair.

When using Leukase N, consider the following precautions to ensure safe and effective treatment.

- Allergy assessment: verify no known hypersensitivity to aminoglycosides or framycetin. - Application area: avoid extensive use on large broken skin or mucous membranes. - Eye exposure: keep product away from eyes; if contact occurs, rinse thoroughly with water. - Duration of therapy: limit use to the prescribed period to reduce risk of resistance. - Concomitant ototoxic/nephrotoxic drugs: exercise caution if patient receives systemic agents with similar toxicity profiles. - Pediatric use: use under professional supervision, especially in infants. - Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Framycetin Sulfate may interact with other medications; awareness of these interactions helps prevent reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Systemic aminoglycosides: concurrent use can increase risk of ototoxicity and nephrotoxicity. - Nephrotoxic agents (e.g., vancomycin, loop diuretics): may potentiate renal toxicity if large skin areas are treated. - Ototoxic drugs (e.g., loop diuretics, cisplatin): combined exposure raises risk of hearing loss.

Moderate Interactions (Monitor Closely): - Topical corticosteroids: may diminish antibacterial activity of framycetin. - Silver‑containing dressings: could interfere with drug absorption. - Other topical antibiotics: assess for additive irritation or resistance.